ClinicalTrials.gg
CompletedNCT03023878Updated Sep 14, 2020Results posted

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of Blinatumomab and Investigator's Choice Chemotherapy in High-risk Diffuse Large B-Cell Lymphoma, sponsored by Amgen. Completed at 24 sites in 6 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-09-14.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 217 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Enrollment
392nd of 963
47 · median 37
Started
2017
with 41 others
Phase 2
380 of 1,131
47 open now
Registered
766th of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 392nd largest by enrollment of the 963 interventional ones that give a count, is one of 42 that started in 2017, is one of 380 in phase 2, and was the 766th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.

Read the detailed description

The safety profile of blinatumomab after frontline rituximab (R)-chemotherapy, consisting of either R-CHOP (14 or 21) (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) or R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), or R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide), will be determined. The study will consist of a screening period of up to 14 days, a standard of care (SOC) R-chemotherapy run-in period of approximately 21 weeks, a 12 to 16 week blinatumomab treatment period, a 30-day safety follow-up visit, and a long-term follow-up period that begins after the safety follow-up visit is completed until 1 year from the first dose blinatumomab.

03

Conditions studied

  • High-risk Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study-specific activities/procedures
  • Age ≥ 18 at time of informed consent
  • Subject must have untreated proven high-risk DLBCL defined by atleast one of the following:

    • International Prognostic Index (IPI) for Diffuse Large B-cell Lymphoma 3 to 5 (representing high intermedidate - high ratings),
    • Double-hit or higher or double protein expression
  • performance status ≤ 2.
  • Subject meets the criteria per investigator's institution to receive standard of care (SOC) rituximab-chemotherapy (ie, R-CHOP [14 or 21] or R-DA-EPOCH or R-CHOEP) of 6 cycles. Subjects may be enrolled on study prior to cycle 1 or cycle 2 of SOC R-chemotherapy
  • Adequate organ and bone marrow function determined within 14 days prior to enrollment defined as:

    • Hematological: ≥1*10\^9/L; count ≥75*10\^9/L; ≥8g/dL
    • Renal: ≥50mL/min;
    • Hepatic: /Alanine aminotransferase \<3* (ULN); Total \<2*ULN (unless Gilbert's Disease or if liver involvement with lymphoma)
  • Subject must have completed 6 cycles of SOC R-chemotherapy and achieved CR, PR or stable disease by PET/CT performed 3 weeks (± 3 days) after cycle 6 of SOC R-chemotherapy. Subjects with progressive disease (PD) are not eligible for treatment with blinatumomab and will end the study.

Exclusion criteria

Exclusion Criteria:

  • central nervous system (CNS) pathology requiring treatment such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, and psychosis
  • Evidence of CNS involvement with DLBCL at disease evaluation obtained prior to starting blinatumomab
  • Current disease or history of autoimmune disease with potential of CNS involvement
  • Subject has active infection requiring systemic therapy
  • Prior anti-CD19 therapies
  • Known infection with or chronic infection with virus or virus
  • History of other within the past 3 years with the following exceptions:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment and felt to be at low risk for recurrence by the treating physician
    • Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease
    • Adequately treated cervical carcinoma in situ without evidence of disease
    • Adequately treated breast ductal carcinoma in situ without evidence of disease
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer
    • Adequately treated urothelial papillary non-invasive carcinoma or carcinoma in situ
  • Subject has known to immunoglobulins or any of the products or components to be administered during dosing.
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge.
  • History/evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed while receiving blinatumomab and for an additional 48 hours after the last treatment dose of blinatumomab.
  • Currently receiving treatment in another device or drug study or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time. An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days. There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death.

    Drug: Blinatumomab · Drug: Investigator's Choice Chemotherapy · Drug: Dexamethasone

Interventions

  • Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.

    Also known as: AMG103, BlinCyto

  • DrugInvestigator's Choice Chemotherapy

    During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows: * R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone) * R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or * R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide).

  • Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).

    Also known as: corticosteroid

06

What researchers measure

Primary outcomes

  1. Participants With Treatment-Emergent (Blinatumomab) Adverse Events

    Overall incidence and severity of treatment-emergent adverse events occurring during the blinatumomab investigative product (IP) treatment period graded by investigators according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.

    Time frame: From the start of first infusion of IP to 30 days after the end of last infusion of IP; median (min, max) treatment duration was 56 (16, 84) days

  2. Participants With Treatment-Emergent Adverse Events Related to Blinatumomab Treatment

    Overall incidence and severity of treatment-emergent adverse events deemed by investigators to be related to blinatumomab treatment. Severity was graded by investigators according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.

    Time frame: From the start of first infusion of IP to 30 days after the end of last infusion of IP; median (min, max) treatment duration was 56 (16, 84) days

Secondary outcomes

  1. Overall Objective Response Rate (ORR) Expressed as the Percentage of Participants Achieving Complete Metabolic Response (CMR) and Partial Metabolic Response (PMR) Using Lugano 2014 Criteria During Cycle 1 and During Treatment Period

    Tumor response assessment was performed by a central reader according to modified Lugano classification using PET/CT scan. Overall objective response rate (ORR) is the percentage of participants with a best overall response of complete metabolic response (CMR) or partial metabolic response (PMR). CMR: a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with/without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PMR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline.

    Time frame: Cycle 1: Day 78 (3 weeks following end of Cycle 1 IP treatment) Treatment Period: Either the Cycle 1 timeframe or approximately Day 128 (3 weeks after Cycle 2 ended) for participants who completed Cycle 2

  2. Kaplan-Meier Estimates for Duration of Response

    Duration of response was calculated only for responders during cycle 1. For participants who had CR or PR on the PET/CT scan at the end of the run-in period, response was measured from the start of blinatumomab treatment. For participants who had stable disease at the end of the run-in period, duration was calculated from documentation of the first assessment of either PR or CR on blinatumomab. Progression was defined as the first diagnosis of progressive metabolic response/progressive disease based on PET/CT scan per central or investigator review during the treatment period or relapse based on clinical tumor assessment during the long-term follow up period. Response duration was calculated until the start of new anti-tumor treatment (excluding any stem cell transplantation), PD, or death, whichever was the earliest event. Participants who did not have new anti-tumor treatment (excluding stem cell transplantation), PD, or death were censored at the last tumor assessment date.

    Time frame: The median (range) follow-up time was 11.5 (8.2, 14.5) months

  3. Complete Response Rate Expressed as the Percentage of Participants Achieving Complete Metabolic Response (CMR) Using Lugano 2014 Criteria During Cycle 1 and During Treatment Period

    Tumor response assessment was performed by a central reader according to modified Lugano classification using PET/CT scan. CMR: a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with/without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology.

    Time frame: Cycle 1: Day 78 (3 weeks following end of Cycle 1 IP treatment) Treatment Period: Either the Cycle 1 timeframe or approximately Day 128 (3 weeks after Cycle 2 ended) for participants who completed Cycle 2

  4. Kaplan-Meier Estimates for Overall Survival (OS) From First Dose of Blinatumomab

    OS was calculated as the time from the date of first IP infusion until death due to any cause. Participants who are alive at the date that triggers the analysis were censored at the date last known to be alive. Months were calculated as days from the first dose date of blinatumomab to death/censor date, divided by 30.5.

    Time frame: The median (range) follow-up time was 12.0 (10.7, 14.5) months.

  5. Kaplan-Meier Estimates for Progression Free Survival (PFS) From First Dose of Blinatumomab

    PFS was calculated as the time from the date of first IP infusion until the date of diagnosis of progression of DLBCL or the date of death, whichever was the earliest. The diagnosis of progression of DLBCL was defined as the first diagnosis of progressive metabolic response/progressive disease based on PET/CT scan per central or investigator review during the treatment period or relapse based on clinical tumor assessment during the long-term follow up period. Participants who were alive and did not have progression were censored at the last evaluable non-missing tumor assessment date prior to the analysis trigger date.

    Time frame: The median (range) follow-up time was 12.0 (8.2, 14.5)

  6. Percentage of Participants Who Had Hematopoietic Stem Cell Transplantation (HSCT)

    Percentage of participants who had HSCT during the Long Term Follow-Up Period.

    Time frame: Day 1 up to 14.5 months

  7. Pharmacokinetics (PK) Results for Blinatumomab: Steady-State Concentrations at Week 1, Week 2 and Week 3 for Cycle 1

    The steady-state serum concentration (Css), summarized as the observed concentrations collected after at least 10 hours after the start of continuous IV infusion. PK blood samples were analyzed in a central lab.

    Time frame: Day 2 at least 24 hours after blinatumomab was started and on Day 9 and Day 16 at least 24 hours after blinatumomab dose was increased in the cycle

  8. Pharmacokinetics (PK) Results for Blinatumomab: Clearance for Cycle 1

    PK blood samples were analyzed in a central lab.

    Time frame: Day 2 at least 24 hours after blinatumomab was started and on Day 9 and Day 16 at least 24 hours after blinatumomab dose was increased in the cycle

07

Results

Posted Mar 26, 2020

Participant flow

This study was conducted at 12 centers in the European Union (France, Germany, Spain, and the United Kingdom), the United States, and Canada. Of the 54 subjects screened, 47 subjects were enrolled.

Pre-Study Run-In Period
Participant flow — Pre-Study Run-In Period
MilestoneBlinatumomab
Started47
Completed30
Not completed17
Withdrew: Protocol-specified criteria11
Withdrew: Death1
Withdrew: Withdrawal by subject5
Between Run-In and Treatment Periods
Participant flow — Between Run-In and Treatment Periods
MilestoneBlinatumomab
Started30
Completed28
Not completed2
Withdrew: Protocol-specified criteria2
Treatment Period
Participant flow — Treatment Period
MilestoneBlinatumomab
Started28
Started cycle 128
Started cycle 211
Completed25
Not completed3
Withdrew: Disease progression1
Withdrew: Withdrawal by subject1
Withdrew: Adverse event1
Long Term Follow-Up Period
Participant flow — Long Term Follow-Up Period
MilestoneBlinatumomab
Started28
Completed26
Not completed2
Withdrew: Death2

Outcome measures

PrimaryParticipants With Treatment-Emergent (Blinatumomab) Adverse Events

Overall incidence and severity of treatment-emergent adverse events occurring during the blinatumomab investigative product (IP) treatment period graded by investigators according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.

Time frame:
From the start of first infusion of IP to 30 days after the end of last infusion of IP; median (min, max) treatment duration was 56 (16, 84) days
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent (Blinatumomab) Adverse Events
ParticipantsBlinatumomab
TEAE28
TEAE severity grade >=311
TEAE severity grade >=45
Serious TEAE7
TEAE leading to interruption of IP3
Serious TEAE leading to interruption of IP2
TEAE leading to discontinuation of IP2
Serious TEAE leading to discontinuation of IP1
Fatal TEAEs0
PrimaryParticipants With Treatment-Emergent Adverse Events Related to Blinatumomab Treatment

Overall incidence and severity of treatment-emergent adverse events deemed by investigators to be related to blinatumomab treatment. Severity was graded by investigators according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and based on the scale: Grade 1 = Mild - transient or mild discomfort; Grade 2 = Moderate - mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required; Grade 3 = Severe - marked limitation in activity, assistance usually required; medical intervention required, hospitalization is possible; Grade 4 = Life threatening - extreme limitation in activity, assistance required; medical intervention, hospitalization or hospice care probable; Grade 5 = death.

Time frame:
From the start of first infusion of IP to 30 days after the end of last infusion of IP; median (min, max) treatment duration was 56 (16, 84) days
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events Related to Blinatumomab Treatment
ParticipantsBlinatumomab
Treatment-related TEAE23
Related TEAE severity grade >=39
Related TEAE severity grade >=43
Related Serious TEAE5
Related TEAE leading to interruption of IP3
Related Serious TEAE leading to interruption of IP2
Related TEAE leading to discontinuation of IP2
Related Serious TEAE leading to discon of IP1
Related and Fatal TEAEs0
SecondaryOverall Objective Response Rate (ORR) Expressed as the Percentage of Participants Achieving Complete Metabolic Response (CMR) and Partial Metabolic Response (PMR) Using Lugano 2014 Criteria During Cycle 1 and During Treatment Period

Tumor response assessment was performed by a central reader according to modified Lugano classification using PET/CT scan. Overall objective response rate (ORR) is the percentage of participants with a best overall response of complete metabolic response (CMR) or partial metabolic response (PMR). CMR: a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with/without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PMR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline.

Time frame:
Cycle 1: Day 78 (3 weeks following end of Cycle 1 IP treatment) Treatment Period: Either the Cycle 1 timeframe or approximately Day 128 (3 weeks after Cycle 2 ended) for participants who completed Cycle 2
Reported as:
Number · percentage of participants
Overall Objective Response Rate (ORR) Expressed as the Percentage of Participants Achieving Complete Metabolic Response (CMR) and Partial Metabolic Response (PMR) Using Lugano 2014 Criteria During Cycle 1 and During Treatment Period
percentage of participantsBlinatumomab
Cycle 189.3 (71.8 to 97.7)
Entire Treatment Period92.9 (76.5 to 99.1)
SecondaryKaplan-Meier Estimates for Duration of Response

Duration of response was calculated only for responders during cycle 1. For participants who had CR or PR on the PET/CT scan at the end of the run-in period, response was measured from the start of blinatumomab treatment. For participants who had stable disease at the end of the run-in period, duration was calculated from documentation of the first assessment of either PR or CR on blinatumomab. Progression was defined as the first diagnosis of progressive metabolic response/progressive disease based on PET/CT scan per central or investigator review during the treatment period or relapse based on clinical tumor assessment during the long-term follow up period. Response duration was calculated until the start of new anti-tumor treatment (excluding any stem cell transplantation), PD, or death, whichever was the earliest event. Participants who did not have new anti-tumor treatment (excluding stem cell transplantation), PD, or death were censored at the last tumor assessment date.

Time frame:
The median (range) follow-up time was 11.5 (8.2, 14.5) months
Reported as:
Median · months
Kaplan-Meier Estimates for Duration of Response
monthsBlinatumomab
Kaplan-Meier Estimates for Duration of ResponseNA (NA to NA)
SecondaryComplete Response Rate Expressed as the Percentage of Participants Achieving Complete Metabolic Response (CMR) Using Lugano 2014 Criteria During Cycle 1 and During Treatment Period

Tumor response assessment was performed by a central reader according to modified Lugano classification using PET/CT scan. CMR: a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with/without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology.

Time frame:
Cycle 1: Day 78 (3 weeks following end of Cycle 1 IP treatment) Treatment Period: Either the Cycle 1 timeframe or approximately Day 128 (3 weeks after Cycle 2 ended) for participants who completed Cycle 2
Reported as:
Number · percentage of participants
Complete Response Rate Expressed as the Percentage of Participants Achieving Complete Metabolic Response (CMR) Using Lugano 2014 Criteria During Cycle 1 and During Treatment Period
percentage of participantsBlinatumomab
Cycle 185.7 (67.3 to 96.0)
Entire Treatment Period89.3 (71.8 to 97.7)
SecondaryKaplan-Meier Estimates for Overall Survival (OS) From First Dose of Blinatumomab

OS was calculated as the time from the date of first IP infusion until death due to any cause. Participants who are alive at the date that triggers the analysis were censored at the date last known to be alive. Months were calculated as days from the first dose date of blinatumomab to death/censor date, divided by 30.5.

Time frame:
The median (range) follow-up time was 12.0 (10.7, 14.5) months.
Reported as:
Median · months
Kaplan-Meier Estimates for Overall Survival (OS) From First Dose of Blinatumomab
monthsBlinatumomab
Kaplan-Meier Estimates for Overall Survival (OS) From First Dose of BlinatumomabNA (NA to NA)
SecondaryKaplan-Meier Estimates for Progression Free Survival (PFS) From First Dose of Blinatumomab

PFS was calculated as the time from the date of first IP infusion until the date of diagnosis of progression of DLBCL or the date of death, whichever was the earliest. The diagnosis of progression of DLBCL was defined as the first diagnosis of progressive metabolic response/progressive disease based on PET/CT scan per central or investigator review during the treatment period or relapse based on clinical tumor assessment during the long-term follow up period. Participants who were alive and did not have progression were censored at the last evaluable non-missing tumor assessment date prior to the analysis trigger date.

Time frame:
The median (range) follow-up time was 12.0 (8.2, 14.5)
Reported as:
Median · months
Kaplan-Meier Estimates for Progression Free Survival (PFS) From First Dose of Blinatumomab
monthsBlinatumomab
Kaplan-Meier Estimates for Progression Free Survival (PFS) From First Dose of BlinatumomabNA (NA to NA)
SecondaryPercentage of Participants Who Had Hematopoietic Stem Cell Transplantation (HSCT)

Percentage of participants who had HSCT during the Long Term Follow-Up Period.

Time frame:
Day 1 up to 14.5 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Hematopoietic Stem Cell Transplantation (HSCT)
percentage of participantsBlinatumomab
Percentage of Participants Who Had Hematopoietic Stem Cell Transplantation (HSCT)3.6 (0.1 to 18.3)
SecondaryPharmacokinetics (PK) Results for Blinatumomab: Steady-State Concentrations at Week 1, Week 2 and Week 3 for Cycle 1

The steady-state serum concentration (Css), summarized as the observed concentrations collected after at least 10 hours after the start of continuous IV infusion. PK blood samples were analyzed in a central lab.

Time frame:
Day 2 at least 24 hours after blinatumomab was started and on Day 9 and Day 16 at least 24 hours after blinatumomab dose was increased in the cycle
Reported as:
Mean · pg/mL
Pharmacokinetics (PK) Results for Blinatumomab: Steady-State Concentrations at Week 1, Week 2 and Week 3 for Cycle 1
pg/mLBlinatumomab
Cycle 1 Week 1: 9 mcg/day288 ± 289
Cycle 1 Week 2: 28 mcg/day795 ± 280
Cycle 1 Week 3: 112 mcg/day3160 ± 782
SecondaryPharmacokinetics (PK) Results for Blinatumomab: Clearance for Cycle 1

PK blood samples were analyzed in a central lab.

Time frame:
Day 2 at least 24 hours after blinatumomab was started and on Day 9 and Day 16 at least 24 hours after blinatumomab dose was increased in the cycle
Reported as:
Mean · L/Hour
Pharmacokinetics (PK) Results for Blinatumomab: Clearance for Cycle 1
L/HourBlinatumomab
Pharmacokinetics (PK) Results for Blinatumomab: Clearance for Cycle 11.61 ± 0.496

Adverse events

Collected over Mortality is reported for all enrolled participants from enrollment in the Run-in Period to the end of long-term follow-up. Adverse events are reported from the first dose of blinatumomab through 30 days after last dose; median duration of treatment was 56 days. In addition, serious adverse events related to blinatumomab collected during the long-term follow-up period are reported; median time on follow-up was 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab3/47 (6.4%)7/28 (25%)26/28 (92.9%)
Most frequent serious events
Most frequent serious events
EventBlinatumomab
PyrexiaGeneral disorders2/28
NeutropeniaBlood and lymphatic system disorders1/28
BacteraemiaInfections and infestations1/28
PneumoniaInfections and infestations1/28
SepsisInfections and infestations1/28
AphasiaNervous system disorders1/28
NeurotoxicityNervous system disorders1/28
Most frequent other events
Showing 10 of 41
Most frequent other events
EventBlinatumomab
PyrexiaGeneral disorders10/28
TremorNervous system disorders10/28
FlushingVascular disorders9/28
FatigueGeneral disorders8/28
CoughRespiratory, thoracic and mediastinal disorders8/28
HeadacheNervous system disorders7/28
NauseaGastrointestinal disorders5/28
Cytokine release syndromeImmune system disorders5/28
ArthralgiaMusculoskeletal and connective tissue disorders5/28
Back painMusculoskeletal and connective tissue disorders5/28

Baseline characteristics

The full analysis set included all participants who received at least 1 dose of blinatumomab.

Age, Continuous
Age, Continuous(years)Blinatumomab
Mean60.2 ± 11.1
Age, Customized
Age, Customized(Participants)Blinatumomab
< 65 years18
>=65 years10
<75 years25
>=75 years3
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab
Female18
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Blinatumomab
Hispanic or Latino7
Not Hispanic or Latino21
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Blinatumomab
Asian1
Black and African American2
Native Hawaiian or Other Pacific Islander0
White21
Other4
Disease Stage at Time of Diagnosis
Disease Stage at Time of Diagnosis(Participants)Blinatumomab
Stage I0
Stage IE1
Stage II0
Stage III5
Stage IV22
International Prognostic Index Score at Diagnosis
International Prognostic Index Score at Diagnosis(Participants)Blinatumomab
Score 22
Score 317
Score 47
Score 52
08

Study locations

24 sites
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Maywood, Illinois 60153, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    New Brunswick, New Jersey 08903, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Sault Ste. Marie, Ontario P6B 0A8, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Créteil Cedex, 94010, France
  • Research Site
    Paris Cedex 10, 75475, France
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Sevilla, Andalucía 41013, Spain
  • Research Site
    Salamanca, Castilla León 37007, Spain
  • Research Site
    Barcelona, Cataluña 08003, Spain
  • Research Site
    L Hospitalet De Llobregat, Cataluña 08907, Spain
  • Research Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Research Site
    A coruña, Galicia 15006, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Bristol, BS2 8ED, United Kingdom
  • Research Site
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martin Garcia-Sancho A, Rodriguez-Garcia G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, Gonzalez-Barca E. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. doi: 10.1080/10428194.2022.2064981. Epub 2022 May 3. PubMed 35503708 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Apr 2019, 24 months.

Results were first posted in Mar 2020, 11 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 24 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2016
First posted
Jan 18, 2017
StartActual
Mar 13, 2017
Primary completionActual
Apr 4, 2019
CompletionActual
Oct 28, 2019
Results first posted
Mar 26, 2020
Last update
Sep 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03023878
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 18, 2017
Start date
Mar 13, 2017
Primary completion
Apr 4, 2019
Completion
Oct 28, 2019
Results posted
Mar 26, 2020
Last update
Sep 14, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion